Trends of Mycobacterium bovis Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance
- PMID: 26421930
- PMCID: PMC4589280
- DOI: 10.1371/journal.pntd.0004124
Trends of Mycobacterium bovis Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance
Abstract
Background: Mycobacterium tuberculosis causes the majority of tuberculosis (TB) cases in humans; however, in developing countries, human TB caused by M. bovis may be frequent but undetected. Human TB caused by M. bovis is considered a zoonosis; transmission is mainly through consumption of unpasteurized dairy products, and it is less frequently attributed to animal-to-human or human-to-human contact. We describe the trends of M. bovis isolation from human samples and first-line drug susceptibility during a 15-year period in a referral laboratory located in a tertiary care hospital in Mexico City.
Methodology/principal findings: Data on mycobacterial isolates from human clinical samples were retrieved from the laboratory's database for the 2000-2014 period. Susceptibility to first-line drugs: rifampin, isoniazid, streptomycin (STR) and ethambutol was determined. We identified 1,165 isolates, 73.7% were M. tuberculosis and 26.2%, M. bovis. Among pulmonary samples, 16.6% were M. bovis. The proportion of M. bovis isolates significantly increased from 7.8% in 2000 to 28.4% in 2014 (X(2)trend, p<0.001). Primary STR resistance was higher among M. bovis compared with M. tuberculosis isolates (10.9% vs.3.4%, p<0.001). Secondary multidrug resistance (MDR) rates were 38.5% and 34.4% for M. bovis and M. tuberculosis, respectively (p = 0.637). A rising trend of primary STR monoresistance was observed for both species (3.4% in 2000-2004 vs. 7.6% in 2010-2014; p = 0.02).
Conclusions/significance: There is a high prevalence and a rising trend of M. bovis isolates in our region. The proportion of pulmonary M. bovis isolates is higher than in previous reports. Additionally, we report high rates of primary anti-tuberculosis resistance and secondary MDR in both M. tuberculosis and M. bovis. This is one of the largest reports on drug susceptibility of M. bovis from human samples and shows a significant proportion of first-line anti-tuberculosis drug resistance.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Detection of a streptomycin-resistant Mycobacterium bovis strain through antitubercular drug susceptibility testing of Tunisian Mycobacterium tuberculosis complex isolates from cattle.BMC Vet Res. 2018 Sep 29;14(1):296. doi: 10.1186/s12917-018-1623-9. BMC Vet Res. 2018. PMID: 30268120 Free PMC article.
-
Human multidrug-resistant Mycobacterium bovis infection in Mexico.Tuberculosis (Edinb). 2015 Dec;95(6):802-809. doi: 10.1016/j.tube.2015.07.010. Epub 2015 Aug 13. Tuberculosis (Edinb). 2015. PMID: 26299906
-
Molecular characterization of Mycobacterium bovis isolates from patients with tuberculosis in Baja California, Mexico.Infect Genet Evol. 2014 Oct;27:1-5. doi: 10.1016/j.meegid.2014.06.020. Epub 2014 Jul 2. Infect Genet Evol. 2014. PMID: 24997332
-
The management of tuberculosis: epidemiology, resistance and monitoring.Dan Med Bull. 2010 Nov;57(11):B4213. Dan Med Bull. 2010. PMID: 21055374 Review.
-
Mycobacterium bovis cervical lymphadenitis: A representative case and review.Int J Pediatr Otorhinolaryngol. 2015 Nov;79(11):1798-801. doi: 10.1016/j.ijporl.2015.09.007. Epub 2015 Sep 10. Int J Pediatr Otorhinolaryngol. 2015. PMID: 26388186 Review.
Cited by
-
Diversity of glpK Gene and Its Effect on Drug Sensitivity in Mycobacterium bovis.Infect Drug Resist. 2022 Apr 2;15:1467-1475. doi: 10.2147/IDR.S346724. eCollection 2022. Infect Drug Resist. 2022. PMID: 35401008 Free PMC article.
-
Zoonotic tuberculosis in Africa: challenges and ways forward.Lancet. 2016 Nov 19;388(10059):2460-2461. doi: 10.1016/S0140-6736(16)32186-9. Lancet. 2016. PMID: 27871735 Free PMC article. No abstract available.
-
Phylogenetically Informative Mutations in Drug Resistance Genes of Human-Infecting Mycobacterium bovis.Transbound Emerg Dis. 2024 Sep 26;2024:5578214. doi: 10.1155/2024/5578214. eCollection 2024. Transbound Emerg Dis. 2024. PMID: 40303120 Free PMC article.
-
Evaluation of Susceptibility to Antimycobacterial Drugs in Mycobacterium Tuberculosis Complex Strains Isolated from Cattle in Poland.J Vet Res. 2017 Apr 4;61(1):23-26. doi: 10.1515/jvetres-2017-0003. eCollection 2017 Mar. J Vet Res. 2017. PMID: 29978051 Free PMC article.
-
Antimicrobial usage and resistance in beef production.J Anim Sci Biotechnol. 2016 Dec 12;7:68. doi: 10.1186/s40104-016-0127-3. eCollection 2016. J Anim Sci Biotechnol. 2016. PMID: 27999667 Free PMC article. Review.
References
-
- Cosivi O, Meslin FX, Daborn CJ, Grange JM (1995) Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Rev Sci Tech 14: 733–746. - PubMed
-
- Torres-Gonzalez P, Soberanis-Ramos O, Martinez-Gamboa A, Chavez-Mazari B, Barrios-Herrera MT, et al. (2013) Prevalence of latent and active tuberculosis among dairy farm workers exposed to cattle infected by Mycobacterium bovis . PLoS Negl Trop Dis 7: e2177 10.1371/journal.pntd.0002177 - DOI - PMC - PubMed
-
- Evans JT, Smith EG, Banerjee A, Smith RM, Dale J, et al. (2007) Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person-to-person transmission in the UK. Lancet 369: 1270–1276. - PubMed
-
- LoBue PA, Betacourt W, Peter C, Moser KS (2003) Epidemiology of Mycobacterium bovis disease in San Diego County, 1994–2000. Int J Tuberc Lung Dis 7: 180–185. - PubMed
-
- Grange JM (2001) Mycobacterium bovis infection in human beings. Tuberculosis (Edinb) 81: 71–77. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical